Effects and efficacy: Sodium para-aminosalicylate enteric-coated tablets are suitable for pulmonary and extrapulmonary tuberculosis caused by Mycobacterium tuberculosis, and are mainly used as second-line anti-tuberculosis drugs. This product is only effective against mycobacteria, and is ineffective against atypical mycobacteria. When this product is used alone, Mycobacterium tuberculosis can quickly develop drug resistance to this product, so it must be used in combination with other anti-tuberculosis drugs. Streptomycin and isoniazid can delay the development of drug resistance of Mycobacterium tuberculosis to the former two when used in combination with sodium para-aminosalicylate enteric-coated tablets. Usage and dosage: Sodium para-aminosalicylate enteric-coated tablets are used orally, and the specific dosage should be strictly followed according to the doctor's instructions. The same drugs produced by different manufacturers may have inconsistent contents in the instructions. If you find that the contents of the drug instructions are inconsistent before taking the medicine, please consult a doctor or pharmacist in time. Adults: 0.5g/tablet preparation, 4 to 6 tablets at a time, 16 to 24 tablets a day, 4 times a day. Children: 0.2 to 0.3g/kg per day according to body weight; divided into 3 to 4 times, the daily dose for children shall not exceed 12g. Drug contraindications: Contraindicated if allergic to this product Related dosage forms: Enteric-coated tablets

Overview Ledipasvir-sofosbuvir tablets are antiviral drugs, which are a combination of ledipasvir and sofosbuvir. Ledipasvir is an inhibitor of HCV NS5A protein. Sofosbuvir is an inhibitor of HCV NS5B RNA-dependent RNA polymerase. What are the conditions for use? It is used to treat chronic hepatitis C virus (HCV) infection in adults and adolescents aged 12 to <18 years. How to take? It can be taken on an empty stomach or with food. Sit or stand and swallow the whole tablet with 200ml of warm water. Do not chew or crush the film-coated tablet. How much to take? (Take as directed by a doctor or as follows) For adults and adolescents aged 12-18 years, the recommended dose of this product is one tablet once a day. It is suitable for the recommended duration of treatment for adults and adolescents (12-18 years) with HCV genotype 1, 2, 4, 5 or 6 HCV mono-infection and HCV/HIV-1 co-infection. Adults and adolescents 12 years or older with HCV genotype 1, 4, 5, or 6: [Patients without cirrhosis] Take 12 weeks of Ledipasvir-Sofosbuvir. For patients with genotype 1 infection who have not been treated previously, consider 8 weeks of Ledipasvir-Sofosbuvir. [Patients with compensated cirrhosis] Take 12 weeks of Ledipasvir-Sofosbuvir plus ribavirin A, or 24 weeks of Ledipasvir-Sofosbuvir without ribavirin. For patients who are considered to be at low risk of clinical disease progression and have options for subsequent retreatment, consider 12 weeks of Ledipasvir-Sofosbuvir without ribavirin. [Patients without cirrhosis or after liver transplantation with compensated cirrhosis] Take 12 weeks of Ledipasvir-Sofosbuvir plus ribavirin A. For patients who are not suitable for or cannot tolerate ribavirin, consider 12 weeks (patients without cirrhosis) or 24 weeks (patients with cirrhosis) of Ledipasvir-Sofosbuvir Tablets (without ribavirin). [Patients with decompensated cirrhosis (regardless of transplant status)] Take 12 weeks of Ledipasvir-Sofosbuvir Tablets + Ribavirin B. For patients who are not suitable for or cannot tolerate ribavirin, consider 24 weeks of Ledipasvir-Sofosbuvir Tablets (without ribavirin). Adults and adolescents 12 years or older with genotype 3 HCV: [Patients with compensated cirrhosis and/or previous treatment failure] Take 24 weeks of Ledipasvir-Sofosbuvir Tablets + Ribavirin A. Adult patients with genotype 2 HCV: Take 12 weeks of Ledipasvir-Sofosbuvir Tablets. A Adults: Weight-based ribavirin (<75kg=1,000 mg, ≥75kg=1,200 mg), divided into two doses to be taken orally with food. Adolescents: For ribavirin dosing recommendations, see the following ribavirin dosing regimens recommended for adolescent patients aged 12 to <18 years. B For ribavirin dosing recommendations for patients with decompensated cirrhosis, see below. Ribavirin dosing recommendations for patients with decompensated cirrhosis when administered in combination with Ledipasvir Sofosbuvir Tablets: [Patients with Child-Pugh-Turcotte (CPT) B cirrhosis before transplantation] For patients weighing <75kg, the dose is 1000mg/day; for patients weighing ≥75kg, the dose is 1200mg/day. [Pre-transplant CPT C cirrhosis; post-transplant CPT B or C cirrhosis] The starting dose is 600 mg, and if well tolerated, the dose can be increased to a maximum of 1000/1200 mg (1000 mg for patients weighing <75 kg; 1200 mg for patients weighing ≥75 kg). If the starting dose is poorly tolerated, the dose should be reduced based on hemoglobin levels as clinically indicated. If a more normalized ribavirin dose (by weight and renal function) cannot be achieved for tolerability reasons, 24 weeks of ledipasvir/sofosbuvir + ribavirin should be considered to minimize the risk of relapse. The following ribavirin dosing regimen is recommended for adolescent patients 12 to <18 years of age when given in combination with ledipasvir-sofosbuvir tablets, where the ribavirin dose is given twice daily with food: [Weight <47 kg]: The dose used is 15 mg/kg/day. 【Weight 47-49kg】: The dosage is 600mg/day. 【Weight 50-65kg】: The dosage is 800mg/day. 【Weight 66-74kg】: The dosage is 1000mg/day. 【Weight> or =75kg】: The dosage is 1200mg/day. Guidelines for adjusting the dose of ribavirin in adults when used with Ledipasvir-Sofosbuvir tablets: 【Hemoglobin level in patients without heart disease】 If <10g/dL, the dose of ribavirin should be reduced to 600mg/day. If <8.5g/dL, ribavirin should be discontinued. 【Hemoglobin level in patients with a stable history of heart disease】 If <10g/dL, the dose of ribavirin should be reduced to 600mg/day, and the hemoglobin decrease should be ≥2g/dL during any 4-week treatment period. If <8.5g/dL, ribavirin should be discontinued, and levels remain <12g/dL despite dose reduction during 4 weeks of treatment. After ribavirin is discontinued due to laboratory abnormalities or clinical abnormalities, an attempt can be made to restart ribavirin at 600 mg per day and further increase the dose to 800 mg per day. However, it is not recommended to increase ribavirin to the originally assigned dose (1000mg-1200mg per day). If vomiting occurs within 5 hours of taking the drug, a second tablet should be taken. If vomiting occurs more than 5 hours after taking the drug, no second dose is required.

Omadacycline tosylate is a product that Zai Lab introduced from Paratek* in 2017. It was launched in the United States in February 2019. On December 16, 2021, the indications of omadacycline tosylate (Neuzai) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin soft structure infection (ABSSSI) were officially approved by the National Medical Products Administration (NMPA). ABSSSI is a bacterial infection with a lesion area of ​​at least 75cm2 (the lesion area is calculated based on the measured congestion/erythema, edema or nodules and range), and the patient is also accompanied by systemic symptoms such as lymphadenopathy or fever (oral temperature ≥38℃). Common pathogens include Streptococcus pyogenes, other streptococci, and Staphylococcus aureus. Antibacterial activity characteristics This drug is a new tetracycline antibiotic, which is structurally modified on the basis of minocycline. It is designed to overcome bacterial resistance to existing tetracycline drugs and improve broad-spectrum antibacterial activity. According to the Sanford Fever Guidelines, aerobic Gram-positive bacteria with antibacterial activity include Enterococcus faecium, Enterococcus faecalis, VRE (±), MSSA, MRSA, Staphylococcus epidermidis, Staphylococcus lugdunensis, various streptococci (Streptococcus anthracis, Streptococcus pyogenes Group B Streptococcus, Streptococcus pneumoniae and Streptococcus viridans), Jack's Corynebacterium, Enterobacteriaceae resistant to ceftazidime and carbapenems, such as ESBL-producing Escherichia coli, KPC enzyme-producing Escherichia coli, MBL-producing Escherichia coli and Klebsiella pneumoniae producing the corresponding enzymes, ampicillin-resistant Haemophilus influenzae, Acinetobacter (Acinetobacter baumannii), MRSA, Stenotrophomonas maltophilia, etc. It has little activity against Pseudomonas aeruginosa, Proteus Morganella and Providencia. The antibacterial spectrum is almost the same as that of tigecycline. Pharmacokinetic characteristics and differences of tigecycline Picture The drug has both intravenous and oral preparations, and the bioavailability of the oral preparation is 34.5%. The protein binding rate is 20%, and the half-life is 15.5~16.8 hours. The protein binding rate of tigecycline is 71-89%, the half-life is 42%, and the blood-brain barrier permeability of tigecycline is 0. Pharmaceutical trials and clinical pharmacology show that the pharmacokinetics (PK) of omadacycline tosylate is not affected by the patient's age, gender, liver and kidney function, etc. After entering the body, it is not metabolized and excreted from the feces. The corresponding patients do not need to adjust the dose when taking the drug. However, the dose of tigecycline needs to be reduced when the Child Pugh score is C. Image Recommended dose Indications Route of administration Day 1 Maintenance CAP Intravenous 200mg (infusion over 60min) 100mg, once a day 100mg, two doses 100ng, once a day Oral 300mg, two doses 300mg, once a day ABSSSI Intravenous 200mg (infusion over 60min) 100mg, once a day 100mg, two doses 100mg, once a day Oral 450mg, qd first and second day 300mg, once a day Image Precautions for taking medicine Image The reconstituted solution of this medicine is orange or dark orange liquid. Use 100ml saline or 5% glucose. Do not use the same infusion line with drugs containing other cations such as calcium ions, magnesium ions, etc. If it is an oral preparation, fast for four hours before administration, fast for 2 hours after administration, and fast for dairy products and foods containing multivitamins for 4 hours after administration. *(Partek Pharmaceuticals was founded in 1996 and is headquartered in Boston, Massachusetts, USA. It is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic drugs based on biology and tetracycline chemistry to meet critical medical needs in the treatment of infectious diseases.)